Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 707 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

NCT02985749
View directory record Official record
Conditions
Autism Spectrum Disorder, Pervasive Developmental Disorder, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 5, 2026, 3:38 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS for Investigating Memory Facilitation

NCT05462782
View directory record Official record
Conditions
Age-associated Memory Impairment
Interventions
Transcranial Magnetic Stimulation (TMS) Cone Coil, Transcranial Magnetic Stimulation (TMS) Sham Coil
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
60 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

NCT01197911
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 5, 2026, 3:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

NCT01176578
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Aerobic Exercise Training
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
50 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 5, 2026, 3:38 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

NCT03282513
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AG-120 (Ivosidenib)
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT03161015
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 5, 2026, 3:38 PM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development and Validation of a PTSD-Related Functional Impairment Scale

NCT00651872
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Not listed
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Silver Springs, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 5, 2026, 3:38 PM EDT
Recruiting Phase 2 Interventional

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

NCT06727773
View directory record Official record
Conditions
Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment, Cognitive Decline, Cognitive Change, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Memantine, Placebo medication, Exercise Intervention, Exercise Control
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

NCT00785551
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
quinine sulfate
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 5, 2026, 3:38 PM EDT
Enrolling by invitation Not applicable Interventional

Effect of PEEP on Cardiac Function

NCT07531602
View directory record Official record
Conditions
Cardiac Surgery Subjects
Interventions
EIT Guided PEEP Trial
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

NCT04469920
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 5, 2026, 3:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 5, 2026, 3:38 PM EDT
Completed No phase listed Observational

Brain Imaging, Nutrition, and Cognition in Breast Cancer Survivors

NCT05122000
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

NCT05611957
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
LY3437943
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Bulevirtide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease

NCT07659964
View directory record Official record
Conditions
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Metronome
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)

NCT01766180
View directory record Official record
Conditions
Memory Impairment
Interventions
Fruitflow-II, resVida
Drug
Lead sponsor
Neurolgy Institute for Brain Health and Fitness
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Sep 5, 2026, 3:38 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

LpD3.5 Intervention Study in Older Adults- LISA-I Trial

NCT07794956
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognition, Brain Aging, Microbiome Dysbiosis, Leaky Gut Syndrome, Gut Inflammation, Inflammaging
Interventions
LpD3.5, Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854
View directory record Official record
Conditions
Renal Impairment
Interventions
ISIS 681257
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 5, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

NCT01289080
View directory record Official record
Conditions
Schizophrenia, Psychiatric Disorders
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 5, 2026, 3:38 PM EDT